Company intelligence / Profile preview

Skandigen

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Skandigen was a Swedish investment company that specialized in the life sciences, biotechnology, and technology sectors. The firm focused on identifying and developing high-growth potential companies, providing both capital and strategic management expertise to its portfolio. Its investment strategy primarily targeted the Nordic region, with significant holdings in healthcare-related firms such as Vitrolife and Karolinska Development. In 2010, Skandigen merged with Bure Equity, effectively ceasing to operate as an independent entity while its portfolio was integrated into the larger group.

Industry: Investors

Beyond the preview

Go deeper on Skandigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skandigen.

Explore the full profile